Walter Stadler
Section of Hematology / Oncology
Professor of Medicine
Fred C. Buffet Professor of Medicine; Chief, Section of Hematology/Oncology; Director, Genitourinary Oncology Program; Chair, UCCRC Clinical Trails Review Committee;Associate Dean for Clinical Research
Referring Physician Access Line: 1-877-DOM-2730

Training

DegreeYearInstitutionArea
BS1984University of IllinoisChemistry
MD1988Yale University 
Residency1991Michael Reese HospitalInternal Medicine
Fellowship1994The University of ChicagoHematology/Oncology

Academic Interests

Dr. Stadler focuses on the treatment of patients with kidney, bladder, prostate, and testes cancer. His research interests are related to new drug development for these patients. To this end he continues to design and conduct phase I, II, and III clinical trials. He is also active in developing new blood based, pathologic, and imaging markers to assist in monitoring of therapy and predicting patient outcome.


Clinical Interests

Kidney cancer, prostate cancer, testicular cancer, bladder cancer


Representative Publications

  1. Medved M, Karczmar G, Yang C, Dignam J, Gajewski TJ, Kindler H, Vokes E, MacEneany P, Mitchell MT, Stadler WM. Semi-quantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time. J. Magn Reson Imaging 20:122-128,2004
  2. Vogelzang NJ, Stadler WM. Kidney Cancer. Lancet 352:1691-1696, 1998
  3. Stadler WM, Huo D, George C, Yang X, Ryan CW, Karrison T, Zimmerman TM, Vogelzang NJ. Prognostic Factors for Survival to Gemcitabine Plus 5-FU Based Regimens in Metastatic Renal Cancer. J Urol 170:1141-1145, 2003
  4. Stadler WM, Hayden A, von der Maase H, Roychowdhury D, Dogliotti L, Seymour L, Kaufman D, Moore M. Long term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urologic Oncology 7:153-157, 2002
  5. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18:1921-1927, 2000